Celcuity Raises $248.7 Million Through Stock and Notes

An update from Celcuity ( (CELC) ) is now available.

On July 30, 2025, Celcuity Inc. entered into an underwriting agreement to issue and sell shares of common stock and pre-funded warrants, completing the offering on July 31, 2025, with net proceeds of approximately $91.6 million. The company also announced a concurrent offering of $175 million in convertible senior notes due 2031, with the combined offerings expected to generate net proceeds of about $248.7 million, intended for working capital and general corporate purposes. The decision not to enter into capped call transactions may lead investors to hedge their equity price risk through other means, potentially impacting the market price of Celcuity’s common stock and convertible notes.

The most recent analyst rating on (CELC) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Celcuity stock, see the CELC Stock Forecast page.

Spark’s Take on CELC Stock

According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.

Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.

To see Spark’s full report on CELC stock, click here.

More about Celcuity

Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for treating multiple solid tumor indications. Their lead therapeutic candidate, gedatolisib, is a potent inhibitor targeting the PI3K/AKT/mTOR pathway, and is currently being evaluated in various clinical trials for advanced breast cancer and metastatic castration-resistant prostate cancer. The company is headquartered in Minneapolis.

Average Trading Volume: 843,992

Technical Sentiment Signal: Buy

Current Market Cap: $1.5B

Find detailed analytics on CELC stock on TipRanks’ Stock Analysis page.